Tau pathology in Huntington’s disease: A brief in vivo PET-imaging report
Objective: To assess feasibility of measuring pathological tau deposition in patients with Huntington's disease (HD) using [18F]-AV-1451 (f.k.a. T807) PET. Background: HD is a progressive…Single-subject FDG PET patterns and cognitive dysfunctions in Parkinson’s disease
Objective: To evaluate [18]FDG-PET single-subject perfusion patterns in Parkinson's disease (PD) patients and their relationship with cognitive dysfunction and progression during five years of follow-up.…Striatal molecular alterations in Huntington’s disease gene expansion carriers: A systematic review and meta-analysis of PET studies
Objective: To systematically examine the evidence of striatal molecular alterations in premanifest and manifest Huntington's disease gene expansion carriers (HDGECs) as measured by Positron emission…The evaluation of metabolic differences by using 18F-FDG-PET/CT in demented and non demented Idiophatic Parkinson’s disease patients
Objective: The objective of this study was to identify metabolic group differences between Idiopatic Parkinson's disease patients with dementia (PDD) and without dementia (PD), by…Dysphagia in early stage Huntington’s disease (HD) – Pilot observations from a multimodal imaging study
Objective: To assess the central neural control of swallowing in HD patients with mild dysphagia using a multimodal imaging approach combining qualitative and quantitative swallowing…Metabolic brain changes related to specific cognitive impairment in non-demented Parkinson’s disease patients
Objective: To measure the expression of the Parkinson's disease related cognitive pattern (PDCP) in 18F-FDG-PET brain images of Parkinson's disease (PD) patients and healthy controls…Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington’s disease gene carriers
Objective: Using positron emission tomography (PET) with [11C]IMA107, we investigated the in vivo expression of PDE10A in extra-striatal regions in a cohort of 12 early…Targeted over-expression with AAV-mediated human α-synuclein in a rat model of Parkinson’s disease – Validation of novel fine motor functional effects
Objective: Targeted over-expression of human α-synuclein using viral-vector mediated gene delivery into the substantia nigra of rats and non-human primates has been reported to lead…Substantia nigra α4β2 nicotinic cholinergic receptor expression correlates with tremor in Parkinson’s disease
Objective: To investigate the relationship between tremor and α4β2 nicotinic cholinergic receptor (nAChR) expression in brain regions associated with tremor in Parkinson's disease (PD), including…Novel PET Tracers of alpha-synuclein for the diagnosis of Parkinson’s disease
Objective: The aim of our project is to develop small molecular weight compounds (Morphomers™) which bind selectively to alpha-synuclein (aSyn) aggregates, in order to generate…